Table 1.

Distribution of the 96 patients used in the study according to the type of cohort (original versus validation), adenocarcinoma (colon, pancreas, prostate), and immunotherapy treatment (Tx: GVAX only, GVAX plus ipilimumab, or ipilimumab only). The clinical setting, trial number, and presence or absence of thyroglobulin antibodies at baseline are also shown.

Type of cohort	Type of adenocarcinoma	Type of immunotherapy	Clinical setting	Clinical trial number	Total serum samples	Total patients	Patients without Tg Abs at baseline	Patients who developed TgAbs after Tx
original	Colon	GVAX only	Metastatic	NCT00656123	16	8	4	3
original	Pancreatic	GVAX only	Resected	NCT00389610	71	12	10	10
validation	Pancreatic	GVAX only	Resected	NCT00389610	48	14	11	6
original	aPancreatic	GVAX + Ipi	Metastatic	NCT00836407	74	15	12	9
original	bProstate	GVAX + Ipi	Metastatic	NCT01510288	126	27	26	21
original	aPancreatic	Ipi only	Metastatic	NCT00836407	47	12	10	0
original	cProstate	Ipi only*	Metastatic	NCT00323882	52	8	8	0
					434	96	81	46

Patients published by

^aLe DT et al. in J Immunotherapy 2013;

^bvan den Eertwegh AJ et al. In Lancet Oncology 2012;

^cSlovin SF et al in Ann Oncol 2013.

^*Patients who also received radiotherapy.